Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors

Annals of Oncology : Official Journal of the European Society for Medical Oncology
H BoerJ A Gietema

Abstract

The success of cisplatin-based (Platinol, Bristol-Myers Squibb Company, New York, NY, USA) chemotherapy for testicular cancer comes at the price of long-term and late effects related to healthy tissue damage. We assessed and modelled serum platinum (Pt) decay after chemotherapy and determined relationships between long-term circulating Pt levels and known late effects. In 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-h urine samples were collected during follow-up (1-13 years after treatment). To build a population pharmacokinetic model, measured Pt data were simultaneously analysed, together with cisplatin dose, age, weight and height using the NONMEM software. Based on this model, area under the curve between 1 and 3 years after treatment (Pt AUC1-3 years) was calculated for each patient. Predicted long-term Pt exposure was related to renal function and to late effects of treatment assessed median 9 (3-15) years after chemotherapy. Decay of Pt was best described by a two-compartment model. Mean terminal T1/2 was 3.7 (range 2.5-5.2) years. Pt AUC1-3 years correlated with cumulative cisplatin dose, and creatinine clearance before and 1 year after treatment. Patients with paraesthesia ha...Continue Reading

References

Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C C BergerH J Schmoll
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S D FossåD R Olsen
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J NuverJ A Gietema
Aug 7, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Janine NuverJourik A Gietema
Jul 7, 2005·British Journal of Cancer·R A HuddartD P Dearnaley
May 4, 2006·British Journal of Clinical Pharmacology·Yan FengRobert R Bies
Oct 25, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S HaugnesR M Bremnes
Mar 15, 2008·Cancer·David J VaughnEmile R Mohler
Sep 18, 2008·BMC Clinical Pharmacology·Elke E M BrouwersJan H M Schellens
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mette SprautenLois B Travis
Sep 26, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hege S HaugnesSophie D Fosså
Nov 8, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E C de HaasJ A Gietema
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chunkit FungLois B Travis
Nov 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J LauritsenG Daugaard
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J LauritsenG Daugaard

❮ Previous
Next ❯

Citations

Dec 3, 2015·Expert Opinion on Pharmacotherapy·Christoph OingCarsten Bokemeyer
Apr 14, 2016·Thrombosis Research·Tone SvilaasPieter W Kamphuisen
Jul 7, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan Oldenburg, Jourik A Gietema
May 4, 2017·Current Opinion in Oncology·Hampig Raphael Kourie, Jean A Klastersky
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ChovanecC Albany
Nov 23, 2017·Nature Communications·Andrew M BreglioLisa L Cunningham
Jul 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harmke J GrootMichael Schaapveld
Mar 9, 2019·Expert Opinion on Pharmacotherapy·Winfried AlsdorfChristoph Oing
Mar 12, 2019·The Cochrane Database of Systematic Reviews·Esmee Cm KooijmansMargreet A Veening
Dec 6, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Chunkit FungLois B Travis
May 28, 2019·Frontiers in Endocrinology·Sandro La VigneraRosita A Condorelli
Apr 18, 2018·Advances in Urology·Amanda F Saltzman, Nicholas G Cost
Nov 11, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·N KhanalLawrence H Einhorn
Apr 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah L KernsUNKNOWN Platinum Study Group
Mar 13, 2019·Frontiers in Endocrinology·Giuseppe SchepisiUgo De Giorgi
Nov 4, 2020·Expert Review of Anticancer Therapy·Kristyna KozakovaMichal Chovanec
Nov 6, 2020·European Heart Journal Cardiovascular Imaging·Anders W BjerringSebastian I Sarvari
Jul 13, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew R TrendowskiM Eileen Dolan
Aug 16, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Max KatesTrinity J Bivalacqua
Jul 16, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sarita DepaniJames Nicholson
Apr 2, 2021·Circulation Research·Daan C H van DorstNinian N Lang
Nov 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ChovanecC Albany
Jun 30, 2021·Der Urologe. Ausg. A·Isabella M Zraik, Yasmine Heß-Busch

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

SPSS
NONMEM
PLT Tools

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.